|
Are REMS Evaluations Working? Not great, says FDA
The FDA is questioning whether surveys and other assessment methods drugmakers are using to evaluate whether risk evaluation and mitigation strategies (REMS) work.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives